Cibc World Market Inc. decreased its holdings in Morgan Stanley (NYSE:MS – Free Report) by 3.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 517,476 shares of the financial services provider’s stock after selling 18,347 shares during the quarter. Cibc World Market Inc.’s holdings in Morgan Stanley were worth $91,868,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Morgan Stanley by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 119,718,100 shares of the financial services provider’s stock valued at $21,253,554,000 after buying an additional 1,361,940 shares in the last quarter. Capital International Investors raised its position in shares of Morgan Stanley by 0.6% in the 3rd quarter. Capital International Investors now owns 27,321,214 shares of the financial services provider’s stock valued at $4,343,523,000 after buying an additional 167,487 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Morgan Stanley by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 27,070,557 shares of the financial services provider’s stock valued at $4,786,350,000 after buying an additional 534,708 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Morgan Stanley by 2.1% in the 4th quarter. Fisher Asset Management LLC now owns 25,018,335 shares of the financial services provider’s stock valued at $4,441,505,000 after buying an additional 524,189 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Morgan Stanley in the 4th quarter valued at approximately $2,736,648,000. Institutional investors and hedge funds own 84.19% of the company’s stock.
Insider Buying and Selling
In related news, insider Eric F. Grossman sold 11,118 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $190.75, for a total transaction of $2,120,758.50. Following the completion of the transaction, the insider directly owned 169,403 shares in the company, valued at $32,313,622.25. This represents a 6.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew M. Saperstein sold 51,668 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $188.59, for a total transaction of $9,744,068.12. Following the transaction, the insider owned 282,142 shares of the company’s stock, valued at approximately $53,209,159.78. This represents a 15.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 77,476 shares of company stock worth $14,644,762 in the last three months. 0.17% of the stock is owned by corporate insiders.
Morgan Stanley Price Performance
Morgan Stanley (NYSE:MS – Get Free Report) last released its quarterly earnings data on Wednesday, April 15th. The financial services provider reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.02 by $0.41. The business had revenue of $20.58 billion during the quarter, compared to analysts’ expectations of $19.23 billion. Morgan Stanley had a net margin of 14.65% and a return on equity of 17.70%. The firm’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.60 EPS. Research analysts anticipate that Morgan Stanley will post 11.85 EPS for the current fiscal year.
Morgan Stanley Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Thursday, April 30th were given a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date was Thursday, April 30th. Morgan Stanley’s dividend payout ratio is currently 36.23%.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on MS. BNP Paribas Exane boosted their target price on shares of Morgan Stanley from $195.00 to $205.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Evercore boosted their target price on shares of Morgan Stanley from $190.00 to $210.00 and gave the company an “outperform” rating in a research report on Thursday, April 16th. Zacks Research cut shares of Morgan Stanley from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 27th. BMO Capital Markets boosted their target price on shares of Morgan Stanley from $190.00 to $220.00 and gave the company an “outperform” rating in a research report on Monday, April 20th. Finally, UBS Group boosted their target price on shares of Morgan Stanley from $196.00 to $214.00 in a research report on Wednesday, May 6th. Twelve equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $205.95.
Check Out Our Latest Stock Report on Morgan Stanley
Key Headlines Impacting Morgan Stanley
Here are the key news stories impacting Morgan Stanley this week:
- Positive Sentiment: Morgan Stanley and Goldman Sachs were reportedly chosen to lead Anthropic’s IPO, a potentially high-profile assignment that could bring underwriting fees, trading activity, and prestige if the deal moves forward. Morgan Stanley and Goldman Sachs Land Anthropic IPO
- Positive Sentiment: A separate report said Morgan Stanley Expansion Capital led a $33 million growth financing for Subtle Medical, reinforcing the firm’s active role in funding AI-related and healthcare technology opportunities. Morgan Stanley Expansion Capital Leads $33 Million Growth Financing For Subtle Medical
- Neutral Sentiment: Morgan Stanley also published macro commentary warning that Federal Reserve Chair Kevin Warsh’s first policy meeting could jolt foreign-exchange markets, a view that matters more for the broader market backdrop than for MS directly. Warsh’s Fed Debut Is a Key Risk for FX, Morgan Stanley Says
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a global financial services firm headquartered in New York City. Founded in 1935 by Henry S. Morgan and Harold Stanley, the company provides a broad range of investment banking, securities, wealth management and investment management services to corporations, governments, institutions and individual investors. Leadership has been guided by a senior executive team and board of directors; James P. Gorman has served as the company’s chief executive and chairman in recent years.
The firm’s primary business activities are organized around three principal businesses: Institutional Securities, Wealth Management and Investment Management.
Read More
- Five stocks we like better than Morgan Stanley
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Want to see what other hedge funds are holding MS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Morgan Stanley (NYSE:MS – Free Report).
Receive News & Ratings for Morgan Stanley Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morgan Stanley and related companies with MarketBeat.com's FREE daily email newsletter.
